INT185916

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 2005
Last Reported 2008
Negated 2
Speculated 0
Reported most in Body
Documents 16
Total Number 20
Disease Relevance 4.27
Pain Relevance 0.53

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

RNA binding (NAF1) nucleus (NAF1) ribosome biogenesis (NAF1)
cytoplasm (NAF1)
Anatomy Link Frequency
nipple 3
plasma 2
epithelial cells 1
NAF1 (Homo sapiens)
Pain Link Frequency Relevance Heat
imagery 60 95.80 Very High Very High Very High
COX-2 inhibitor 15 82.96 Quite High
anesthesia 30 71.24 Quite High
Pain 30 67.84 Quite High
alcohol 15 54.48 Quite High
cINOD 15 5.00 Very Low Very Low Very Low
aspirin 10 5.00 Very Low Very Low Very Low
vincristine 5 5.00 Very Low Very Low Very Low
peptic ulcer disease 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Breast Cancer 400 99.92 Very High Very High Very High
Malignant Neoplastic Disease 50 98.72 Very High Very High Very High
Endometriosis (extended) 95 97.52 Very High Very High Very High
Hyperplasia 135 93.32 High High
Cancer 80 89.68 High High
Congenital Anomalies 30 77.84 Quite High
Pain 30 67.84 Quite High
Carcinoma In Situ 15 49.96 Quite Low
Lobular Carcinoma 15 49.64 Quite Low
Noninfiltrating Intraductal Carcinoma 40 38.96 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Forty-two percent of women with a lactation history produced NAF while 34% of women who never lactated were fluid producers (p < 0.10).
Gene_expression (produced) of NAF
1) Confidence 0.65 Published 2005 Journal BMC Womens Health Section Body Doc Link PMC1198234 Disease Relevance 0.36 Pain Relevance 0
Forty-eight percent of nulliparous women were fluid producers whereas 36% of parous women produced NAF, which is not statistically significant for the group of pre-menopausal women (p <= 1.0), but is significant if all women are included (p < 0.05).
Gene_expression (produced) of NAF associated with endometriosis (extended)
2) Confidence 0.65 Published 2005 Journal BMC Womens Health Section Body Doc Link PMC1198234 Disease Relevance 0.23 Pain Relevance 0.03
Even though not all women produce NAF, Wrensch et al [9] showed that women who produce nipple fluid had a slight (1.5 times) increase in the relative risk of breast cancer development and non-producers had a decreased relative risk compared to all fluid producers regardless of final diagnosis.
Gene_expression (produce) of NAF in nipple associated with breast cancer
3) Confidence 0.65 Published 2005 Journal BMC Womens Health Section Body Doc Link PMC1198234 Disease Relevance 0.21 Pain Relevance 0
Thirty-six percent of subjects with no 1st degree family history produced NAF, 46% of subjects with one 1st degree relative with breast cancer, and 75% of subjects who had more than one 1st degree relative with breast cancer (p <= 0.10).
Gene_expression (produced) of NAF associated with breast cancer
4) Confidence 0.65 Published 2005 Journal BMC Womens Health Section Body Doc Link PMC1198234 Disease Relevance 0.35 Pain Relevance 0
Any collected NAF was transferred from the nipple or sample collection cup(s) to a vial of fixative (CytoLyt, Cytyc Corporation, Boxborough, MA) using a pipette if necessary.
Gene_expression (transferred) of NAF in nipple
5) Confidence 0.65 Published 2005 Journal BMC Womens Health Section Body Doc Link PMC1198234 Disease Relevance 0 Pain Relevance 0.03
Only one attempt was made to obtain NAF in the five minute session, and if no NAF was produced by either breast, the participant was considered to be a non-producer.


Neg (no) Gene_expression (produced) of NAF
6) Confidence 0.65 Published 2005 Journal BMC Womens Health Section Body Doc Link PMC1198234 Disease Relevance 0 Pain Relevance 0
Thirty-nine percent of Caucasians produced NAF while NAF was obtained from 31% of non-white subjects (p <= 1.0).
Gene_expression (produced) of NAF
7) Confidence 0.65 Published 2005 Journal BMC Womens Health Section Body Doc Link PMC1198234 Disease Relevance 0.32 Pain Relevance 0
NAF production and cytologic assessment may be used in conjunction with the Gail model for risk prediction and the automated HALO system may facilitate NAF collection in the office setting.
Gene_expression (production) of NAF
8) Confidence 0.65 Published 2005 Journal BMC Womens Health Section Body Doc Link PMC1198234 Disease Relevance 0.35 Pain Relevance 0.20
The result of NAF producers and non-producers were expressed as raw numbers for each demographic category.
Gene_expression (producers) of NAF
9) Confidence 0.58 Published 2005 Journal BMC Womens Health Section Body Doc Link PMC1198234 Disease Relevance 0 Pain Relevance 0.05
This device has an advantage over other methods of NAF collection in that it is automatic and easy to use, thereby removing most clinician variability.
Gene_expression (collection) of NAF
10) Confidence 0.57 Published 2005 Journal BMC Womens Health Section Body Doc Link PMC1198234 Disease Relevance 0.15 Pain Relevance 0
Overall, 19% of the subjects produced NAF with adequate cellularity and 1% were found to have cytologic atypia.


Gene_expression (produced) of NAF
11) Confidence 0.51 Published 2005 Journal BMC Womens Health Section Abstract Doc Link PMC1198234 Disease Relevance 0.34 Pain Relevance 0
Wrensch and colleagues have observed in a prospective trial that NAF production and NAF atypia in a screening population are associated with an increased risk of breast cancer.
Gene_expression (production) of NAF associated with breast cancer
12) Confidence 0.51 Published 2005 Journal BMC Womens Health Section Body Doc Link PMC1198234 Disease Relevance 0.35 Pain Relevance 0.09
Wrensch and colleagues have observed in a prospective trial that NAF production and NAF atypia in a screening population are associated with an increased risk of breast cancer.
Gene_expression (production) of NAF associated with breast cancer
13) Confidence 0.51 Published 2005 Journal BMC Womens Health Section Body Doc Link PMC1198234 Disease Relevance 0.35 Pain Relevance 0.09
Thirty-eight percent of participants produced a NAF sample and of the samples obtained, 50% had adequate ductal epithelial cells for cytology analysis and five asymptomatic women (5/500, 1%) had Category III changes (atypical hyperplasia).
Gene_expression (produced) of NAF in epithelial cells associated with hyperplasia
14) Confidence 0.51 Published 2005 Journal BMC Womens Health Section Body Doc Link PMC1198234 Disease Relevance 0.30 Pain Relevance 0
Nipple fluid can be obtained from many women, with reports of NAF production ranging from 25% [11] to more than 95% [12] of women.
Gene_expression (production) of NAF in Nipple
15) Confidence 0.51 Published 2005 Journal BMC Womens Health Section Body Doc Link PMC1198234 Disease Relevance 0.41 Pain Relevance 0
Since celecoxib specifically inhibits COX-2, the PGE2 present in NAF is likely the product of both COX-1 and COX-2 activity, with the downregulation of PGE2 reflecting the action of celecoxib.
Gene_expression (present) of NAF
16) Confidence 0.18 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2259321 Disease Relevance 0.06 Pain Relevance 0.04
In the current study, we confirmed our original observation that PGE2 levels in NAF, but not in plasma, decreased after celecoxib treatment in postmenopausal women, and that the PGE2 response in NAF correlated with plasma celecoxib concentration at the 400 mg bid dose level (figure 1).
Gene_expression (levels) of NAF in plasma
17) Confidence 0.18 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2259321 Disease Relevance 0.15 Pain Relevance 0
In the current study, we confirmed our original observation that PGE2 levels in NAF, but not in plasma, decreased after celecoxib treatment in postmenopausal women, and that the PGE2 response in NAF correlated with plasma celecoxib concentration at the 400 mg bid dose level (figure 1).
Gene_expression (response) of NAF in plasma
18) Confidence 0.18 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2259321 Disease Relevance 0.14 Pain Relevance 0
The significant decrease in NAF PGE2 that was observed in post- but not premenopausal women is likely because most premenopausal women had low (median 227 ng/ml) celecoxib levels, whereas most postmenopausal women had higher (median 860 ng/ml) levels.
Gene_expression (decrease) of NAF
19) Confidence 0.18 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2259321 Disease Relevance 0.13 Pain Relevance 0
Reasons for not collecting NAF in 5 women at their follow-up visit included: one woman refused, in two women attempts to collect NAF were unsuccessful, and two women yielded less than one microliter of NAF, which we felt was insufficient for reliable analysis of PGE2 (Table 1).
Neg (not) Gene_expression (collecting) of NAF
20) Confidence 0.18 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2259321 Disease Relevance 0.06 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox